Macular Degeneration Treatment Market Size is projected to

New York, United States, June 19, 2023 (GLOBE NEWSWIRE) -- The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see objects. It manifests when the capillaries close to the fovea enlarge and leak. The fluid buildup interferes with light reflection, which causes progressive vision loss. Nutritional therapy can aid treatment in the early stages of dry macular degeneration. A healthy diet rich in antioxidants is part of the plan to sustain the macula's cells.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample

Rising Impact of Retinal Disorder Drivers on the Global Market

The rising prevalence of retinal diseases has increased the demand for macular degeneration treatment. Eye conditions have emerged as potential threats in many developed and developing countries. Globally, the prevalence of the most severe eye conditions is rising, and vision loss is becoming a serious public health concern. Numerous worldwide retinal diseases that impair vision have been identified by the World Health Organization (WHO). Two of these conditions, refractive errors, and age-related macular disorders, are most prevalent in underdeveloped countries. As a result of the rising prevalence of retinal disorders, it is anticipated that the market for treating macular degeneration will expand significantly over the forecast period.

Rapid Aging Population Creates Tremendous Opportunities

According to the UN's World Aging Report, 703 million individuals were 65 or older in 2019. By 2050, this number is anticipated to double. The population aged 65 and older increased globally from 6% in 1990 to 9% in 2019. Smart contact lenses and intelligent optometry are two examples of cutting-edge and digital healthcare products that may impact the market under consideration. Future developments in digital technology could affect eye care. Future access to gene chips could lead to more accurate AMD and glaucoma diagnosis and treatment. Due to investments made by businesses and accelerated research, the market is anticipated to grow during the forecast period.

Report Scope

Report Metric	Details
Market Size by 2030	USD 15,167.69 million
Market Size in 2021	USD 8,208.70 million
CAGR	7.06% (2022-2030)
Historical Data	2019-2020
Base Year	2021
Forecast Period	2022-2030
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Stage of Disease, Route of Administration, Sales Channels
Geographies Covered	North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors	Novartis AG, Pfizer Inc., Panoptica, Bausch Health Companies Inc., Regeneron Pharmaceutical Inc., Aerie Pharmaceutical Inc., REGENXBIO Inc., and Bayer AG
Key Market Opportunities	Rapid Aging Population
Key Market Drivers	Rising Impact of Retinal Disorders Improving Investments in Research and Development

Buy Now Full Report @ https://straitsresearch.com/buy-now/macular-degeneration-treatment-market

Regional Analysis

North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period. The United States represents a sizable portion of the market under study due to several factors, including the burden of the aging population and the prevalence of age-related macular degeneration. The US is dedicated to improving overall population eye health through several initiatives. Along with recent product launches and established healthcare infrastructure, it is also anticipated that the presence of the major market players will hasten the market's expansion in the United States. Novel macular degeneration treatments are expected to fuel market growth in the United States.

Europe is expected to grow at a CAGR of 6.70%, generating USD 3,531.14 million during the forecast period. The aging population, the rising prevalence of macular degeneration, and sizable R&D expenditures are additional factors influencing the expansion of the French market under investigation. In France, there are an increasing number of cutting-edge research studies being carried out. The funding provided by the government, both at the national and EU agency levels, is primarily to blame. Medical costs are covered by the government and the individual in France, which has one of the best healthcare systems. Over the anticipated period, it is anticipated that these campaigns will increase public awareness and spur rapid market growth in France.

The presence of significant market players, the rising elderly population in Japan, and the rising awareness of macular degeneration in Asia-Pacific all point to a substantial expansion of the Japanese market for macular degeneration treatments. Japan is one of the Asian countries that is aging quickly. In June 2019, Sumitomo Dainippon Pharma Co. Ltd. modified its contract with Healios K.K. for joint development initiatives and other cooperative activities in Japan. The modifications concerned the activities of development and commercialization. Joint development activities will generate retinal pigment epithelial cells from iPS cells to treat age-related macular degeneration and other eye diseases. Due to the rising AMD prevalence and research and development efforts in the area, the market for macular degeneration treatments in Japan is anticipated to increase.

Key Highlights

The global macular degeneration treatment market size was valued at USD 8,208.70 million in 2021. It is expected to reach USD 15,167.69 million by 2030, growing at a CAGR of 7.06% during the forecast period (2022–2030).
Based on type, the global macular degeneration treatment market is bifurcated into dry and wet age-related macular degeneration. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period.
Based on the stage of disease, the global macular degeneration treatment market is bifurcated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment owns the highest market share and is expected to grow at a CAGR of 7.03% during the forecast period.
Based on the route of administration, the global macular degeneration treatment market is bifurcated into the intravenous route and intravitreal route. The intravitreal route segment is the highest contributor to the market and is expected to grow at a CAGR of 7.10% during the forecast period.
Based on sales channels, the global macular degeneration treatment market is bifurcated into ambulatory surgical centers and hospitals. The hospital segment owns the highest market share and is expected to grow at a CAGR of 7.04% during the forecast period.
North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period.

Competitors in Macular Degeneration Treatment Market

Novartis AG
Pfizer Inc.
Panoptica
Bausch Health Companies Inc.
Regeneron Pharmaceutical Inc.
Aerie Pharmaceutical Inc.
REGENXBIO Inc.
Bayer AG

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample

Segmentation of Macular Degeneration Treatment Market

By Type

Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration

By Stage of Disease

Early-stage AMD
Intermediate AMD
Late-stage AMD

By Route of Administration

Intravenous Route
Intravitreal Route

By Sales Channels

Ambulatory Surgical Centers
Hospitals
Other Sales Channels

By Regions

North America
Europe
Asia-Pacific
The Middle East and Africa
South America

TABLE OF CONTENT

Executive Summary
Research Scope & Segmentation
1. Research Objectives
2. Market Definition
3. Limitations & Assumptions
4. Market Scope & Segmentation
5. Currency & Pricing Considered
Market Opportunity Assessment
1. Emerging Regions / Countries
2. Emerging Companies
3. Emerging Applications / End Use
4. Investment Landscape
5. New Business Models / Revenue Streams
6. TAM
Market Trends
1. Drivers
2. Market Warning Factors
3. Latest Macro Economic Indicators
4. Geopolitical Impact
5. Human Factors
6. Technology Factors
Market Assessment
1. Porters Five Forces Analysis
2. Value Chain Analysis
3. Sales And Distribution Channel Analysis
4. Case Study Analysis
5. Patent Analysis
6. M & A Agreements & Collabration Analysis
ESG TRENDS
Global Macular Degeneration Treatment Market Size Analysis
1. Global Macular Degeneration Treatment Market Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
North America Market Analysis
1. Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
6. U.S.
7. Canada
Europe Market Analysis
1. Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
6. U.K.
7. Germany
8. France
9. Spain
10. Italy
11. Russia
12. Nordic
13. Benelux
14. Rest Of Europe
APAC Market Analysis
1. Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
6. China
7. Korea
8. Japan
9. India
10. Australia
11. Taiwan
12. South East Asia
13. Rest Of Asia-Pacific
Middle East And Africa Market Analysis
1. Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
6. UAE
7. Turkey
8. Saudi Arabia
9. South Africa
10. Egypt
11. Nigeria
12. Rest Of MEA
LATAM Market Analysis
1. Introduction
2. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-Related Macular Degeneration
    1. By Value
  3. Wet Age-Related Macular Degeneration
    1. By Value
3. By Stage Of Disease
  1. Introduction
    1. Stage Of Disease By Value
  2. Early-Stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-Stage AMD
    1. By Value
4. By Route Of Administration
  1. Introduction
    1. Route Of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
5. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
6. Brazil
7. Mexico
8. Argentina
9. Chile
10. Colombia
11. Rest Of LATAM
Competitive Assessment
1. Adoption Matrix
2. Macular Degeneration Treatment Market Share By Manufacturers
3. Macular Degeneration Treatment Market Ranking By Revenue For Manufacturers
4. Average Price By Manufacturers
5. Vendor Footprint Analysis
Market Players Assessment
1. Novartis AG
  1. Overview
  2. Business Information
  3. Revenue
  4. ASP
  5. Gross Margin
  6. Swot Analysis
  7. Recent Developmments
2. Pfizer Inc.
3. Panoptica
4. Bausch Health Companies Inc.
5. Regeneron Pharmaceutical Inc.
6. Aerie Pharmaceutical Inc.
7. REGENXBIO Inc.
8. Bayer AG.
Research Methodology
1. Research Data
  1. Secondary Data
    1. Major Secondary Sources
    2. Key Data From Secondary Sources
  2. Primary Data
    1. Key Data From Primary Sources
    2. Breakdown Of Primaries
  3. Secondary And Primary Research
    1. Key Industry Insights
2. Market Size Estimation
  1. Bottom-Up Approach
  2. Top-Down Approach
  3. Market Projection
3. Research Assumptions
  1. Assumptions
4. Limitations
5. Risk Assessment
APPENDIX
1. Discussion Guide
2. Customization Options
3. Related Reports
DISCLAIMER

Table of Content and Figure @ https://straitsresearch.com/report/macular-degeneration-treatment-market/toc

Recent Development

In August 2022, Novartis intends to completely spin off the Sandoz division to establish a standalone business.
In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney disease and type 2 diabetes (finerenone).

News Media

Global Macular Degeneration Treatment Market Ascends at a Noteworthy CAGR of 7.06%

Global Lacrimal Devices Market to Grow at a CAGR of 3.5%

Posterior Segment Eye Disorders Market Share Extends at a Healthy CAGR of 4.83% by 2031

Have a Look at the Related Research Report

Eye Health Supplements Market: Information by Supplement Category (Antioxidants), Therapeutic Domain (Age-Related Macular Degeneration), Product Type, and Region — Forecast till 2029

Dry Eye Syndrome Treatment Market: Information by Product (Cyclosporine, Artificial Tears), Dosage Form (Liquid Drops, Gel), Disease Type (Evaporative, Aqueous Deficient), and Regions-Forecast Till 2031

Posterior Segment Eye Disorders Market: Information by Product (Drugs and Devices), Application (Macular Degeneration, Glaucoma, and Diabetic Retinopathy), and Regions—Forecast Till 2031

Eye Tracking Market: Information by Type (Optical, Eye Attached Tracking), Application (Healthcare, Consumer Electronics), Component (Hardware, Software), and Region — Forecast till 2030

Lacrimal Devices Market: Information by Product (Intubation Sets, Stents And Tubes, Dilators), Applications (Glaucoma, Dry Eye, Lacrimal Gland Inflammation), and Regions—Forecast Till 2031

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Macular Degeneration Treatment Market Size is projected to reach USD 15.16 billion by 2030, growing at a CAGR of 7.06%: Straits Research

Mot-clé

Macular Degeneration Treatment Market Size is projected to reach USD 15.16 billion by 2030, growing at a CAGR of 7.06%: Straits Research

Mot-clé

Hyperliens